Cancer Registry Software: Market Size & Forecast 2026

Cancer registry software enables structured capture of demographic, diagnostic, treatment, and outcome data for cancer cases, supporting clinical care, population surveillance, and oncology research. The market was valued near USD 95 million in 2025, with consensus forecasts pointing to a value of roughly USD 260-315 million by 2034-2035. Demand is concentrated among hospitals, central and state cancer registries, academic centers, and pharmaceutical sponsors running outcome studies.

• •Estimated 2025 market size: ~USD 95 million, with projected CAGR of 10-13% across major forecasts.
• •Primary end users: hospital cancer programs, government public-health registries, and academic research institutions.
• •Deployment modes split between on-premise installations at large hospitals and cloud-based subscriptions favored by smaller facilities.

Rising global cancer incidence is expanding the patient population whose data must be captured and tracked, directly increasing registry demand. Regulatory pressure from bodies such as the U.S. CDC's National Program of Cancer Registries and analogous programs in Europe and Asia is making structured electronic reporting compulsory rather than optional. At the same time, the shift toward personalized oncology and evidence-based care requires richer longitudinal datasets, which modern registry platforms are built to deliver.

• •Growing cancer prevalence and aging populations widen the addressable caseload worldwide.
• •Government mandates for electronic cancer reporting and accreditation requirements push hospitals toward certified software.
• •Demand for real-world oncology evidence from pharma and research sponsors adds a new buyer segment beyond traditional public-health users.

The market is commonly segmented by component (software vs. services), deployment (cloud-based vs. on-premise), database type (commercial vs. public/government), and end user (hospitals, research centers, government registries). Cloud-based delivery and commercial database offerings are the fastest-growing sub-segments as buyers prioritize lower upfront cost and easier integration with electronic health records. North America leads on revenue share thanks to established CDC and SEER-style infrastructure, while Asia-Pacific is the fastest-growing region on the back of expanding national cancer control programs.

• •Cloud-based deployment is outpacing on-premise growth as hospitals modernize IT infrastructure.
• •North America holds the largest regional share; Asia-Pacific shows the highest growth rate due to new registry programs in China, India, and Southeast Asia.
• •Commercial databases are gaining share over government-maintained systems in research-oriented deployments.

What are the recent trends and outlook?

The strongest near-term trend is the migration of registry workloads from on-premise databases to secure cloud platforms, which simplifies multi-site data pooling and lowers total cost of ownership. Vendors are also investing in analytics, machine-learning-assisted abstraction, and natural-language processing to reduce the manual case-finding burden on cancer registrars. Looking ahead, deeper integration with genomics, molecular tumor boards, and real-world evidence platforms is expected to redefine registry software from a reporting tool into a strategic oncology data backbone.

• •Cloud migration and SaaS licensing models are reshaping vendor revenue mixes and shortening replacement cycles.
• •AI-assisted data abstraction is emerging as a key differentiator, addressing the shortage of certified tumor registrars.
• •Linkage with genomic and molecular profiling data is positioning registries as core infrastructure for precision-oncology programs.